These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    Author: de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P, French Study Group on Sickle Cell Disease.
    Journal: Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381.
    Abstract:
    Two hundred twenty-five SCD children have been enrolled in a study assessing the tolerability of hydroxyurea treatment. Mean age at inclusion was 9.2+/-4.4 years, median duration of treatment was 3.8 years. Ten and 75 patients have been treated respectively for more than 10 and 5 years. No severe side effect was related to hydroxyurea treatment, which was discontinued in 81 children mainly for treatment failure (30 cases) or non-compliance (17 cases). Treatment was also withdrawn in 5 of 6 children who had developed hypersplenism, in 3 because of a pathological transcranial Doppler, and in 2 after a stroke.
    [Abstract] [Full Text] [Related] [New Search]